Prediction of HLA-A2-restricted CTL epitope specific to HCC by SYFPEITHI combined with polynomial method

World Journal of Gastroenterology

Volumn 11, Issue 2, 2005, Pages 208-211

  Dong, Hai Long ^a   Sui, Yan Fang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cytotoxic T lymphocyte; Epitope; Hepatocellular carcinoma; HLA A*0201

Indexed keywords

ALPHA FETOPROTEIN; EPITOPE; HLA A2 ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 8; PROTEIN P53; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACCURACY; AMINO ACID SEQUENCE; ANALYTIC METHOD; ARTICLE; CANCER IMMUNOTHERAPY; COMPUTER PROGRAM; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; DRUG DESIGN; HUMAN; LIVER CELL CARCINOMA; PREDICTION; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; SCORING SYSTEM;

EID: 12344262690     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i2.208     Document Type: Article

References (26)

1. Dong HL, Sui YF, Li ZS, Qu P, Wu W, Ye J, Zhang XM, Lu SY. Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro. Cancer Lett 2004; 211: 219-225
2. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-1647
3. Katsura F, Eura M, Chikamatsu K, Oiso M, Yumoto E, Ishikawa T. Analysis of individual specific cytotoxic T lymphocytes for two MAGE-3-derived epitopes presented by HLA-A24. Jpn J Clin Oncol 2000; 30: 117-121
4. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001; 50: 3-15
5. Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, El-Kamary SS, Bass EB. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002; 36(5 Suppl 1): S84-S92
6. Butterfield LH, Ribas A. Immunotherapy of hepatocellular carcinoma. Expert Opin Biol Ther 2002; 2: 123-133
7. Ladhams A, Schmidt C, Sing G, Butterworth L, Fielding G, Tesar P, Strong R, Leggett B, Powell L, Maddern G, Ellem K, Cooksley G. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol 2002; 17 889-896
8. Ming LH, Zhu YR, Harris CC, Wang XH, Wu ZY, Sun ZT. Association of HLA-A02 genotype with hepatocellular carcinoma in a prevalent area of China. Chin J Immunol 1999; 15: 305-310
9. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993; 74: 929-937
10. Pascolo S, Schirle M, Guckel B, Dumrese T, Stumm S, Kayser S, Moris A, Wallwiener D, Rammensee HG, Stevanovic S. AMAGE-A1 HLA-A*0201 epitope identified by mass spectrometry. Cancer Res 2001; 61: 4072-4077
11. Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 1998; 59: 1-14
12. van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, De Smet C, Traversari C, Townsend A, Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994; 24: 3038-3043
13. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 1997; 185: 833-841
14. Schirle M, Keilholz W, Weber B, Gouttefangeas C, Dumrese T, Becker HD, Stevanovic S, Rammensee HG. Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol 2000; 30: 2216-2225
15. Butterfield LH, Meng WS, Koh A, Vollmer CM, Ribas A, Dissette VB, Faull K, Glaspy JA, Mcbride WH, Economou JS. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol 2001; 166: 5300-5308
16. Thurner B, Haendle I, Röder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Bröcker EB, Steinman RM, Enk A, Kämpgen E, Schuler G. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 1669-1678
17. Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, Goletz TJ, Avila N, Berzofsky JA, Helman LJ, Mackall CL. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol 2002; 38: 158-164
18. Rammensee HG, Bachmann J, Emmerich NP, Bachor OA, Stevanoviæ S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 213-219
19. Gulukota K, Sidney J, Sette A, DeLisi C. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol 1997; 267: 1258-1267
20. Marshall KW, Wilson KJ, Liang J, Woods A, Zaller D, Rothbard JB. Prediction of peptide affinity to HLA DRB1*0401. J Immunol 1995; 154: 5927-5933
21. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152: 163-175
22. Hammer J, Bono E, Gallazzi F, Belunis C, Nagy Z, Sinigaglia F. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J Exp Med 1994; 180: 2353-2358
23. Hammer J. New methods to predict MHC-binding sequences within protein antigens. Curr Opin Immunol 1995; 7: 263-269
24. Tahara K, Mori M, Sadanaga N, Sakamoto Y, Kitano S, Makuuchi M. Expression of the MAGE gene family in human hepatocellular carcinoma. Cancer 1999; 85: 1234-1240
25. Kobayashi Y, Higashi T, Nouso K, Nakatsukasa H, Ishizaki M, Kaneyoshi T, Toshikuni N, Kariyama K, Nakayama E, Tsuji T. Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma. J Hepatol 2000; 32: 612-617
26. Charuruks N, Tangkijvanich P, Voravud N, Chatsantikul R, Theamboonlers A, Poovorawan Y. Clinical significance of p53 antigen and anti-p53 antibodies in the sera of hepatocellular carcinoma patients. J Gastroenterol 2001; 36: 830-836